133 related articles for article (PubMed ID: 26554863)
21. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
22. Differential gene expression studies in cisplatin-sensitive versus cisplatin-resistant human cancer cell lines.
Gosepath EM; Weykam S; Gruenewald E; Ko Y; Wiese M; Kassack MU
Int J Clin Pharmacol Ther; 2004 Nov; 42(11):637-9. PubMed ID: 15598029
[No Abstract] [Full Text] [Related]
23. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
24. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
25. Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer.
Huanchun Y; Shulan Z; Jing L
Eur J Gynaecol Oncol; 2009; 30(2):181-5. PubMed ID: 19480250
[TBL] [Abstract][Full Text] [Related]
26. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
Ao Q; Su W; Guo S; Cai L; Huang L
Sci Rep; 2015 Nov; 5():16396. PubMed ID: 26548925
[TBL] [Abstract][Full Text] [Related]
27. Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma.
Li C; Li Y; Wang X; Wang Z; Cai J; Wang L; Zhao Y; Song H; Meng X; Ning X; Xu C; Lin M; Li L; Geng J
Histopathology; 2012 May; 60(6):953-63. PubMed ID: 22372608
[TBL] [Abstract][Full Text] [Related]
28. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
29. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
30. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic effect of hyperthermia and chemotherapy with platinum salt on ovarian cancer cells: results of an in vitro study.
Muller M; Chérel M; Dupré PF; Gouard S; Collet M; Classe JM
Eur Surg Res; 2011; 46(3):139-47. PubMed ID: 21372578
[TBL] [Abstract][Full Text] [Related]
32. [Comparative genomic hybridization for analysis of chromosomal changes in cisplatin-resistant ovarian cancer].
Kudoh K; Takano M; Koshikawa T; Yoshida S; Hirai M; Kikuchi Y; Nagata I; Miwa M; Uchida K
Hum Cell; 2000 Sep; 13(3):109-16. PubMed ID: 11197772
[TBL] [Abstract][Full Text] [Related]
33. GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells.
Kullmann M; Kotz S; Hellwig M; Kalayda GV; Metzger S; Jaehde U
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1038-40. PubMed ID: 26521923
[No Abstract] [Full Text] [Related]
34. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
35. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
36. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
37. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
38. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
39. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
